The Food and Drug Administration ( FDA ) has granted accelerated approval to Truseltiq ( Infigratinib ), a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 ( FGFR2 ) fusion or other rearrangement as detected by an FDA-approved test.
The FDA has also approved FoundationOne CDx for selection of patients with FGFR2 fusion or other rearrangement as a companion diagnostic device for treatment with Infigratinib.
Efficacy was demonstrated in CBGJ398X2204, a multicenter open-label single-arm trial, that enrolled 108 patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement as determined by local or central testing.
Patients received Infigratinib 125 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles until disease progression or unacceptable toxicity.
The major efficacy outcome measures were overall response rate ( ORR ) and duration of response ( DoR ), as determined by blinded independent central review according to RECIST 1.1.
The ORR was 23% ( 95% CI: 16, 32 ), with 1 complete response and 24 partial responses. Median DoR was 5 months ( 95% CI: 3.7, 9.3 ).
Among the 23 responders, 8 patients maintained the response for 6 months or more.
The most common ( incidence 20% or more ) adverse reactions were hyperphosphatemia, increased creatinine, nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, vision blurred and vomiting.
The serious risks include hyperphosphatemia and retinal pigment epithelial detachment and monitoring for these adverse reactions during treatment is recommended.
The recommended Infigratinib dose is 125 mg orally once daily on an empty stomach for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. ( Xagena )
Source: FDA, 2021